| No headlines available for RYOAX. |
|
|
| Morningstar Overall Rating: |
 |
| Total Assets: |
5.04M |
| Category: |
Specialty-Health |
| Total Expense Ratio: |
1.87% |
|
| PERFORMANCE & RISK | 31-Dec-07
| YTD Return: |
5.25% |
| 5y Avg Return: |
10.75% |
| Rank in Category (ytd): |
126 |
| % Rank in Category (ytd): |
62.69% |
| Beta (3y): |
1.17 |
| Morningstar Risk Rating: |
High |
|
| The investment seeks capital appreciation. The fund primarily invests in equity securities issued by biotechnology companies that are traded in the United States, as well as in futures and options contracts. Biotechnology companies include those engaged in the research, development, and manufacture of various biotechnological and biomedical products. It is nondiversified. |
|
| Fund Profile |
|
Help
0.11 (0.49%) 
Summary
Add RYOAX to Portfolio 
Download Data
